CABALETTA BIO, INC. Available-for-sale Equity Securities, Gross Unrealized Gain
CABALETTA BIO, INC. (CABA) reported Available-for-sale Equity Securities, Gross Unrealized Gain of $11.00 thousand for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain · last filed 2020-08-06
- CABALETTA BIO, INC. available-for-sale equity securities, gross unrealized gain for the quarter ending 2020-06-30 was $11.00K.
| Period end | Available-for-sale Equity Securities, Gross Unrealized Gain 3 month |
|---|---|
| 2020-06-30 | $11.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |